Literature DB >> 25218715

Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.

Hidenaga Yamamori1, Ryota Hashimoto2, Yuko Fujita3, Shusuke Numata4, Yuka Yasuda5, Michiko Fujimoto5, Kazutaka Ohi5, Satomi Umeda-Yano6, Akira Ito6, Tetsuro Ohmori4, Kenji Hashimoto3, Masatoshi Takeda5.   

Abstract

Hypofunction of the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors may be involved in the pathophysiology of schizophrenia. Many studies have investigated peripheral NMDA receptor-related glutamatergic amino acid levels because of their potential as biological markers. Peripheral d-serine levels and the ratio of d-serine to total serine have been reported to be significantly lower in patients with schizophrenia than in controls. Peripheral d-serine levels and the d-/l-serine ratio have also been reported to significantly increase in patients with schizophrenia as their clinical symptoms improve from the time of admission to the time of discharge. In this study, we examined whether peripheral NMDA receptor-related glutamatergic amino acids levels were altered in patients with treatment-resistant schizophrenia compared to controls and whether these peripheral amino acids levels were altered by clozapine treatment. Twenty-two patients with treatment-resistant schizophrenia and 22 age- and gender-matched healthy controls were enrolled. The plasma levels of d-serine, l-serine, glycine, glutamate, and glutamine were measured before and after clozapine treatment. We found that the plasma levels of d-serine and the d-/l-serine ratio were significantly lower in the patients before clozapine treatment than in the controls. The d-/l-serine ratio was significantly increased by clozapine treatment in patients, and no significant difference was observed in the plasma levels of d-serine and the d-/l-serine ratio between the patients after clozapine treatment and the controls. We also found that plasma glycine levels and the glycine/l-serine ratio were significantly increased following clozapine treatment in the patients, and the glycine/l-serine ratio was significantly higher in the patients after clozapine treatment than in the controls. There was no significant difference in the plasma levels of glutamate and glutamine both between the controls and patients and between before and after clozapine treatment. This study firstly demonstrated changes of d-/l-serine and glycine/l-serine ratio between before and after clozapine treatment, suggesting that the plasma d-/l-serine ratio and glycine/l-serine ratio could be markers of therapeutic efficacy or clinical state in treatment-resistant schizophrenia.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clozapine; Glycine; Plasma; Serine; Treatment-resistant schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25218715     DOI: 10.1016/j.neulet.2014.08.052

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

Review 1.  Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Authors:  Joseph T Coyle; W Brad Ruzicka; Darrick T Balu
Journal:  Am J Psychiatry       Date:  2020-12-01       Impact factor: 18.112

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

Review 3.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

4.  Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.

Authors:  Chien-Yi Kuo; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

Review 5.  Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia.

Authors:  Silas A Buck; M Quincy Erickson-Oberg; Ryan W Logan; Zachary Freyberg
Journal:  Mol Psychiatry       Date:  2022-06-10       Impact factor: 13.437

6.  Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.

Authors:  Glenn Dallérac; Xia Li; Pierre Lecouflet; Nadège Morisot; Silvia Sacchi; Rachel Asselot; Thu Ha Pham; Brigitte Potier; David J G Watson; Staffan Schmidt; Grégoire Levasseur; Pascal Fossat; Andrey Besedin; Jean-Michel Rivet; Joseph T Coyle; Ginetta Collo; Loredano Pollegioni; Jan Kehr; Micaela Galante; Kevin C Fone; Alain M Gardier; Thomas Freret; Angelo Contarino; Mark J Millan; Jean-Pierre Mothet
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

7.  Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects.

Authors:  Yoshihiro Kamada; Ryota Hashimoto; Hidenaga Yamamori; Yuka Yasuda; Tetsuo Takehara; Yuko Fujita; Kenji Hashimoto; Eiji Miyoshi
Journal:  BBA Clin       Date:  2016-02-23

8.  D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures.

Authors:  Alan C Foster; Jill Farnsworth; Genevieve E Lind; Yong-Xin Li; Jia-Ying Yang; Van Dang; Mahmud Penjwini; Veena Viswanath; Ursula Staubli; Michael P Kavanaugh
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

9.  Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T.

Authors:  Reggie Taylor; Elizabeth A Osuch; Betsy Schaefer; Nagalingam Rajakumar; Richard W J Neufeld; Jean Théberge; Peter C Williamson
Journal:  BJPsych Open       Date:  2017-02-02

10.  Schizophrenia and the eye.

Authors:  Steven M Silverstein; Richard Rosen
Journal:  Schizophr Res Cogn       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.